HCPlive (8/18, Butera) reports the FDA “announced clearance for the Deep Transcranial Magnetic Stimulation (Deep TMS™) System, which was developed by BrainsWay Ltd., for the reduction of comorbid anxiety symptoms in adult patients with depression, otherwise known as anxious depression.” The agency’s “decision came after the company submitted data from 573 patients who had undergone Deep TMS treatment in 11 studies, including both randomized controlled trials and open-label studies.” The clearance was announced in an Aug. 18 press release from BrainsWay Ltd.(SOURCE: APA Headlines)